» Articles » PMID: 39453502

Chronic Stress-mediated Dysregulations in Inflammatory, Immune and Oxidative Circuitry Impairs the Therapeutic Response of Methotrexate in Experimental Autoimmune Disease Models

Overview
Specialty Pharmacology
Date 2024 Oct 25
PMID 39453502
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic stress is significantly implicated in the worsening of autoimmune disorders, contributing to elevated inflammation and diminished therapeutic efficacy. Here, in this study, we investigated the detrimental impact of an 8-week chronic unpredictable stress (CUS) protocol on the progression of arthritis and psoriasis using collagen-induced arthritis (CIA) and imiquimod (IMQ)-induced psoriasis rat models, respectively. Our objective was to elucidate how prolonged stress exacerbates disease severity and impairs the effectiveness of treatment drug. Following the induction of CIA and IMQ, rats were subjected to an 8-week CUS paradigm designed to simulate chronic stress conditions. Moreover, after 5 weeks of CUS, methotrexate (MTX; 2 mg/kg, administered once weekly for 3 weeks, intraperitoneally) was introduced as a therapeutic intervention. The severity of CUS-induced effects and the therapeutic impairment of MTX in arthritis and psoriasis rats were assessed through pathological examination of joint and epidermal tissues, respectively. Additionally, we measured various pro-inflammatory cytokine levels, including NF-κB (nuclear factor kappa B), IFN-γ (interferon-gamma), TNF-α (tumour necrosis factor alpha), IL (interleukin)-1β, IL-6, IL-17 and IL-23 using enzyme-linked immunosorbent assay (ELISA), analysed immune cells through complete haematological profiling and evaluated oxidative stress markers. Our findings revealed that CUS significantly aggravated the pathological features of both arthritis and psoriasis. Prolonged stress exposure led to heightened inflammatory responses, increased oxidative stress and more severe tissue damage. Moreover, the therapeutic efficacy of MTX was notably reduced in stressed rats compared to non-stressed, underscoring the detrimental effects of chronic stress on treatment outcomes. Taken together, our results emphasize the importance of considering chronic stress as a critical factor in the management of autoimmune diseases.

References
1.
Acabchuk R, Kamath J, Salamone J, Johnson B . Stress and chronic illness: The inflammatory pathway. Soc Sci Med. 2017; 185:166-170. PMC: 8570552. DOI: 10.1016/j.socscimed.2017.04.039. View

2.
Adefegha S, Okeke B, Oboh G, Ijomone O, Oyeleye S . Modulatory effect of eugenol on arginase, nucleotidase, and adenosine deaminase activities of platelets in a carrageenan-induced arthritis rat model: A possible anti-arthritic mechanism of eugenol. Biomed Pharmacother. 2018; 106:1616-1623. DOI: 10.1016/j.biopha.2018.07.143. View

3.
Agarwal V, Kaushik A, Rehman M, Chaudhary R, Jawaid T, Kamal M . Interleukin-6 expression and its modulation by diacerein in a rat model of chronic stress induced cardiac dysfunction. Heliyon. 2021; 7(12):e08522. PMC: 8665349. DOI: 10.1016/j.heliyon.2021.e08522. View

4.
Agorastos A, Chrousos G . The neuroendocrinology of stress: the stress-related continuum of chronic disease development. Mol Psychiatry. 2021; 27(1):502-513. DOI: 10.1038/s41380-021-01224-9. View

5.
Avitsur R, Stark J, Dhabhar F, Sheridan J . Social stress alters splenocyte phenotype and function. J Neuroimmunol. 2002; 132(1-2):66-71. DOI: 10.1016/s0165-5728(02)00310-7. View